FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
LALPATHLAB
1,720
+53.35 (3.2%)
Updated 03:28 07/07 IST
LALPATHLAB Buy or Sell - FrontPage Forums
0 Users have submitted 0 trade ideas of Rs. 0 for LALPATHLAB
Disclaimer0% Bullish
0% Bearish
LALPATHLAB Buy or Sell - Brokerage Reports
No. of reports in last year
4
No. of analysts
2
Average Consensus Forecast
1274.25
Consensus Potential
-39.37%
LALPATHLAB Ratings
Long term LALPATHLAB rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
3.5/5 (2 Ratings)
Find answers to all your questions on live LALPATHLAB message board: Is LALPATHLAB buy or sell? Should I buy LALPATHLAB shares? Why are LALPATHLAB shares falling? Should I invest in LALPATHLAB stock?
- Home
- LALPATHLAB Forum
LALPATHLAB Share Price Discussion
N
Reputation: 3,913 • Today 10:08 AM
Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
The company, in its Annual Report for 2019-20, stated that instances and situations like the COVID-19 outbreak further boost the importance of diagnostics as an integral part of healthcare system.
The company, in its Annual Report for 2019-20, stated that instances and situations like the COVID-19 outbreak further boost the importance of diagnostics as an integral part of healthcare system.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Today 9:36 AM
Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
The company said it served 1.94 crore patients and processed 4.77 crore samples
The company said it served 1.94 crore patients and processed 4.77 crore samples
The Economic Times
Like
Reply
N
Reputation: 3,913 • Jul 5 6:33 AM
'These tech companies will continue to generate greater returns in future'
I think most pharma stocks are overvalued now, and the rally will stablise now, says Sumit Bilgaiyan, the founder of Equity99.
I think most pharma stocks are overvalued now, and the rally will stablise now, says Sumit Bilgaiyan, the founder of Equity99.
Moneycontrol
Like
Reply
D
Reputation: 17,391 • May 19 5:00 AM
Prabhudas Lilladher target on LALPATHLAB
Date: 19-May-20
Broker: Prabhudas Lilladher
Price @ Call: 1583.35
Target: 895
Recommendation: SELL
Like
Reply
N
Reputation: 3,913 • May 19 4:43 AM
Sell Dr. Lal PathLabs; target of Rs 895: Prabhudas Lilladher
Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.
Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 895 in its research report dated May 19, 2020.
Moneycontrol
Like
Reply
S
Reputation: 34,234 • May 19 1:37 AM
*Result Highlight*
Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY)
Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 eac...
Read more...
3
Reply
N
Reputation: 3,913 • May 9 1:43 AM
Opportunity is pharma is huge, advise investors to invest: Motilal Oswal
As lockdown mode could continue and the government's ability to come out with an aggressive bailout package is limited, it's difficult to make out a case for big upside in the short run.
As lockdown mode could continue and the government's ability to come out with an aggressive bailout package is limited, it's difficult to make out a case for big upside in the short run.
Moneycontrol
Like
Reply
T
Reputation: -5,817 • May 8 4:38 AM
*DR LAL PATHLAB Rs 16.15 CRS NSE BLOCK FOR ~ 100350 SHARES, AT RS 1609.50*
Like
Reply
N
Reputation: 3,913 • May 7 5:33 AM
Drop airlines! Here are top 10 stocks based on Warren Buffett's investment methodology
Warren Buffett once again showed investors as to how one can cut losses and preserve cash. The investing phenomenon is dynamic in nature and usually changes over a period of time based on the prevailing trend.
Warren Buffett once again showed investors as to how one can cut losses and preserve cash. The investing phenomenon is dynamic in nature and usually changes over a period of time based on the prevailing trend.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Apr 30 8:18 AM
Brokerages initiate buy on 11 stocks after COVID-led fall, expect 10-49% upside
Majority of experts started advising clients to accumulate quality stocks in a gradual manner with a long term view
Majority of experts started advising clients to accumulate quality stocks in a gradual manner with a long term view
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Apr 28 1:03 AM
Hot Stocks | Granules India, Dr Lal Path Lab, Navin Flourine are short-term buys
Positional Support for Nifty is seen at 8,900, and unless that is breached, the short-term trend of the market would be considered bullish only.
Positional Support for Nifty is seen at 8,900, and unless that is breached, the short-term trend of the market would be considered bullish only.
Moneycontrol
Like
Reply
T
Reputation: -5,817 • Apr 27 8:28 AM
*DR LAL PATHLAB Rs 16.05 CRS NSE BLOCK FOR ~ 103775 SHARES, AT RS 1546.25*
Like
Reply
N
Reputation: 3,913 • Apr 13 7:43 AM
Analysts suggest these 15 quality mid-caps for 1-year investment horizon
Due to the COVID-19 pandemic, most large and mid-cap stocks have corrected significantly. They are expected to remain volatile unless the issue of coronavirus comes under control.
Due to the COVID-19 pandemic, most large and mid-cap stocks have corrected significantly. They are expected to remain volatile unless the issue of coronavirus comes under control.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Apr 1 7:53 AM
Coronavirus pain may linger; 10 stocks you can consider for your portfolio
Brokerages and analysts are of the view that the pain caused by COVID-19 may linger and the market is factoring in the hit on earnings and economic fallout from coronavirus outbreak.
Brokerages and analysts are of the view that the pain caused by COVID-19 may linger and the market is factoring in the hit on earnings and economic fallout from coronavirus outbreak.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Mar 18 4:58 AM
Thyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testing
The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.
The total number of coronavirus cases in India rose to 147, with 10 fresh cases reported from various parts of the country.
Moneycontrol
Like
Reply
N
Reputation: 3,913 • Mar 18 1:23 AM
Coronavirus pandemic: Private labs can scale up Covid-19 testing by 10x, but safety concerns remain
Despite best efforts, the government labs are only able to do 6,000 tests a day with a waiting period of two days.
Despite best efforts, the government labs are only able to do 6,000 tests a day with a waiting period of two days.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
LALPATHLAB Share Price - Technicals
- NewsBotToday 10:08 AMOutlook for diagnostics industry favourable for growth: Dr Lal PathLabsMoneycontrolNewsBotToday 9:36 AMOutlook for diagnostics industry favourable for growth: Dr Lal PathLabsThe Economic TimesNewsBotMay 19 4:43 AMSell Dr. Lal PathLabs; target of Rs 895: Prabhudas LilladherMoneycontrolNewsBotMay 9 1:43 AMOpportunity is pharma is huge, advise investors to invest: Motilal OswalMoneycontrolNewsBotMay 7 5:33 AMDrop airlines! Here are top 10 stocks based on Warren Buffett's investment methodologyMoneycontrolNewsBotApr 30 8:18 AMBrokerages initiate buy on 11 stocks after COVID-led fall, expect 10-49% upsideMoneycontrolNewsBotApr 28 1:03 AMHot Stocks | Granules India, Dr Lal Path Lab, Navin Flourine are short-term buysMoneycontrolNewsBotApr 13 7:43 AMAnalysts suggest these 15 quality mid-caps for 1-year investment horizonMoneycontrolNewsBotApr 1 7:53 AMCoronavirus pain may linger; 10 stocks you can consider for your portfolioMoneycontrolNewsBotMar 18 4:58 AMThyrocare Tech, Dr Lal PathLabs rise 9% as govt allow private lab to do coronavirus testingMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.